What is osteoporosis?

Postgraduate Medical Journal

Volumn 79, Issue 929, 2003, Pages 133-138

  Christodoulou, C ^b   Cooper, C ^a,b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BENZOTHIOPHENE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN DERIVATIVE; ETIDRONIC ACID; HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TESTOSTERONE; VITAMIN D;

BREAST CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FRAGILITY FRACTURE; HEALTH CARE COST; HIGH RISK PATIENT; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE; MORBIDITY; MORTALITY; NAUSEA; OSTEOPOROSIS; REVIEW; RISK FACTOR; UNITED KINGDOM; VERTEBRA FRACTURE; VOMITING; WRIST FRACTURE;

ALCOHOL DRINKING; BODY WEIGHT; BONE DENSITY; CALCITONIN; CALCIUM; DENSITOMETRY, X-RAY; DIPHOSPHONATES; EXERCISE; FEMALE; FRACTURES, SPONTANEOUS; GLUCOCORTICOIDS; GONADAL STEROID HORMONES; HEALTH CARE COSTS; HUMANS; MALE; NUTRITIONAL STATUS; OSTEOPOROSIS; RISK FACTORS; SMOKING;

EID: 0242668433     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.79.929.133     Document Type: Review

References (46)

1. Consensus Development Conference. Prophylaxis and treatment of osteoporosis. Osteoporosis Int 1991;1:114-7.
2. Royal College of Physicians. Osteoporosis: clinical guidelines for prevention and treatment. London: Royal College of Physicians of London, 1999.
3. Eddy D, Johnston C, Cummings SR, et al. Osteoporosis: review of the evidence for prevention, diognosis, and treatment and cost-effectiveness analysis. Osteoporosis Int 1998;8(suppl 4):S1-80.
4. Black D, Cooper C. Epidemiology of fractures and assessment of fracture risk. Clin Lab Med 2000;20:439-53.
5. Kanis JA and the WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: a synopsis of the WHO report. Osteoporosis Int 1994;4:368-81.
6. Melton LJ, Chrischilles EA, Cooper C, et al. Perspective. How may women have osteoporosis? J Bone Miner Res 1992;7:1005-10.
7. Cooper C. Epidemiology and public health impact of osteoporosis. Clin Rheumatol 1993;7:459-77.
8. Looker AC, Orwoll ES, Johnston CC, et al. Prevalence of low femoral bone density in older US adults. From NHANES III. J Bone Miner Res 1997;12:1761-8.
9. Cooper C, Melton LJ. Magnitude and impact of osteoporosis and fractures. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press, 1996: 419-34.
10. Johnell O, Gullberg B, Allander E, et al. The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporosis Int 1992;2:298-302.
11. Royal College of Physicians of London. Fractured neck of femur: prevention and management. London: Royal College of Physicians, 1989.
12. Cooper C, Atkinson EJ, Jacobsen JJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-5.
13. Browner WS, Sealey DG, Vogt TM, et al. Non-trauma mortality in elderly women with low bone mineral density. Lancet 1991;338:355-8.
14. Chrischilles EA, Butler CD, Davis CS, et al. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151:2026-32.
15. Office of Technology Assessment, Congress of the United States. Hip fracture outcomes in people age 50 and over: mortality, service use, expenditures and long-term functional impairment. Washington, DC: US Department of Commerce Publication, 1993 (NTIS PB 94 107653).
16. Gold DT. The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996;18(suppl 3):S185-9.
17. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997;315:841-6.
18. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-73.
19. Seeman E. The effects of tobacco and alcohol use on bone. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press, 1996: 577-97.
20. Cumming RG, Nevitt MC. Calcium for prevention of osteoporotic fractures in post- menopausal women. J Bone Miner Res 1997;12:1321-9.
21. Snow CM, Shaw JM, Matkin CC. Physical activity and risk of osteoporosis. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. San Diego: Academic Press, 1996: 511-28.
22. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993;341:72-5.
23. Mazess RB, Collick B, Tempe J, et al. Performance evaluation of a dual-energy X-ray bone densitometer. Calcif Tissue Int 1989;44:228-32.
24. Laskey MA, Flaxman ME, Barber RW, et al. Comparative performance in vitro and in vivo of Lunar DPX and Hologic QDR- 1000 dual-energy X-ray absorptiometers. Br J Radiol 1991;64:1023-9.
25. Laskey MA, Crisp AJ, Cole TJ, et al. Comparison of the effect of different reference data on Lunar DPX and Hologic QDR -1000 dual-energy X-ray absorptiometers. Br J Radiol 1992;65:1124-9.
26. Reid IR, Evans MC, Amer R, et al. The influence of osteophytes and aortic calcification on spinal bone mineral density in postmenopausal women. J Clin Endocrino J Metab 1991;72:1372-4.
27. Compston JE, Cooper C, Kanis JA. Bone densitometry in clinical practice. BMJ 1995;310:1507-10.
28. Compston J. Prevention and treatment of osteoporosis. Clinical guidelines and new evidence. J R Coll Physicians Lond 2000;34:518-21.
29. Hodsman AB, Hanley DA, Josse R. Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. Can Med Assoc J 2002;166:1426-30.
30. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
31. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
32. Wu F, Ames R, Clearwater J, et al. Prospective 10-year study of the determinants of bone density and bone boss in normal postmenopausal women, including the effect of hormone replacement therapy. Clin Endocrinol 2002;56:703-11.
33. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
34. Ettinger B, Black D, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.
35. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76.
36. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26.
37. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
38. Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy. N Engl J Med 1991;325:1189-95.
39. Elders PJ, Lips P, Netelenbos JC, et al. Long-term effect of calcium supplementation on bone loss in perimenopausal women. J Bone Miner Res 1994;9:963-70.
40. Dawson-Hughes B. Calcium, vitamin D and vitamin D metabolites. In: Papapoulos SE, Lips P, Pols HAP, et al, eds. Osteoporosis. 96 International Congress Series 1118. Amsterdam: Excerpta Medica, 1996: 299-303.
41. Ooms ME, Roos JC, Bezemer PD, et al. Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab 1995;80:1052-8.
42. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-42.
43. Tilyard MW, Spears GF, Thomson J, et al. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992;326:357-62.
44. Eastell R, Reid DM, Compston J, et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998;244:271-92.
45. Lukert BP, Raisz LG. Gbcocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
46. Adachi JD, Roux C, Pitt PI, et al. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss. J Rheumatol 2000;27:2424-31.